Crassostrea Gigas for Liver Health

Status Not yet recruiting

Clinical Trial Summary

This study aimed to observe whether a hydrolyzed oyster extract improves liver health in participants whose alanine transaminase (ALT) levels are1-3 fold above the normal. A total of 96 participants will be randomly allocated to active (oyster) or placebo group (1:1). Each group will receive 750 mg of oyster extract or placebo per day for 8 weeks. Primary outcome will be the change in ALT level and secondary outcomes will be; (1) ratios of participants with normal ALT, aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT); (2) the change in serum bilirubin; (3) the change in multi-dimensional fatigue inventory; (4) the changes in serum lipids; (5) the changes in antioxidant enzymes.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Fatty Liver
Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver

Clinical Trial Details

NCT number	NCT02992470
Study type	Interventional
Source	Korean Medicine Hospital of Pusan National University
Contact	Jun-Yong Choi, PhD, KMD
Email	orientdoct@gmail.com
Status	Not yet recruiting
Phase	N/A
Start date	December 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04031729` - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease	Phase 1/Phase 2
Recruiting	`NCT03725631` - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD	N/A
Active, not recruiting	`NCT05084404` - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease	Phase 2
Completed	`NCT05081427` - Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2
Recruiting	`NCT05430178` - Metabolic Pathology of Pediatric NAFLD	N/A
Recruiting	`NCT04389593` - Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference
Active, not recruiting	`NCT05199948` - Weight, Energy, Lipids, and the Liver (WELL) Study	N/A
Active, not recruiting	`NCT03696797` - Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease	N/A
Terminated	`NCT02365233` - Fatty Liver Study in Patients With Type II Diabetes	Phase 4
Completed	`NCT05309642` - Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study	N/A
Completed	`NCT03763877` - A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD	Phase 2
Completed	`NCT04828551` - Noninvasive Biomarkers of Metabolic Liver Disease 1.1	N/A
Completed	`NCT05792423` - Conditionally Increased Output (CIO) Enhanced Ultrasound System	N/A
Not yet recruiting	`NCT06335771` - Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity	N/A
Recruiting	`NCT02815891` - A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Not yet recruiting	`NCT05908877` - Cardio-Metabolic Risk Evaluation in Overweight and Obese Children
Not yet recruiting	`NCT04887766` - Study on GS300 on NAFLD	N/A
Completed	`NCT03986684` - Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Recruiting	`NCT05165706` - Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance	N/A
Completed	`NCT04235205` - Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease	Phase 2